Physician profile
Jodi Carbone
NPI 1528500154
$1,542.41
in general payments reported to CMS, 2019-2025
18 companies · $539 in 2025
The $539 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2021: $116 · 2022: $147 · 2023: $329 · 2024: $181 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $214.34 | 2023-2025 | Caplyta |
| Alkermes, INC. | $187.59 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Idorsia Pharmaceuticals US INC | $145.33 | 2023 | Quviviq |
| Medtronic USA, INC. | $135.69 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2023 | Relistor |
| Teva Pharmaceuticals USA, INC. | $115.00 | 2022 | |
| Corium, LLC | $113.20 | 2025 | Azstarys |
| Lilly USA, LLC | $94.49 | 2019 | |
| Lundbeck LLC | $87.78 | 2022-2025 | Abilify Asimtufii |
| Otsuka America Pharmaceutical, INC. | $78.48 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $56.60 | 2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $54.59 | 2025 | Belbuca, Jornay Pm |
| Indivior INC. | $50.08 | 2024 | Perseris, Sublocade |
| Abbvie INC. | $19.15 | 2025 | |
| Almatica Pharma LLC | $18.28 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $16.88 | 2025 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $16.24 | 2025 | |
| Noven Therapeutics, LLC | $13.69 | 2025 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Carbone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.